Market Size in 2021 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 4.75 Billion | USD 10.75 Billion | 7.9% | 2021 |
The global joint pain injections market size was worth around USD 5.82 Billion in 2024 and is predicted to grow to around USD 15.35 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 10.18% between 2025 and 2034.
The report analyzes the global joint pain injections market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the joint pain injections industry.
Joint pain injections are injected directly into the joints for relieving pain along with minimizing swelling as well as discomfort to the patient. Reportedly, joint pain is usually observed in the geriatric population. Moreover, musculoskeletal disorders such as arthritis and sacroiliac joint pain are the root cause of inflammation and pain occurring in the elderly population. Furthermore, the surge in the occurrence of rheumatoid arthritis and osteoarthritis along with the easy availability of cost-effective treatments for these conditions will enhance demand for joint pain injections in the medical sector.
Inactive Lifestyle and Surge In Cases of Osteoarthritis & Rheumatoid Arthritis To Elevate Demand For Joint Pain Injections
A sedentary lifestyle and obesity along with the rise in the occurrence of musculoskeletal disorders such as osteoarthritis and rheumatoid arthritis will carve a profitable growth map for the global joint pain injections market. In addition, growing awareness about the early diagnosis and treatment of joint pain has resulted in proliferating demand for joint pain injections in the healthcare sector.
Huge unmet medical requirements of the population in emerging and under-developed economies will expand the scope of growth of the global market. Furthermore, a rise in healthcare spending by governments of developed countries along with product innovations will foster the expansion of the joint pain injections business across the globe. As per WHO, nearly 2 billion persons across the globe were affected due to musculoskeletal ailments in 2020.
Escalating costs of medical products and unfavorable reimbursement policies impede the global market expansion
Low awareness about joint pain injections in emerging economies along with reduced demand for intra-cellular inoculations for treating joint pains can inhibit the growth of the global joint pain injections industry. Apparently, the lack of favorable compensation policies for joint pain inoculations witnessed across emerging economies along with inflating costs of medical devices across the globe will put brakes on the expansion of the global market.
Increase in patient pool suffering from arthritis to open new facades of growth for the global market
A prominent increase in the geriatric population and surge in the patient population pool suffering from arthritis has resulted in humungous demand for effective treatment for joint pains. This, in turn, has created new growth avenues for the global joint pain injections industry. In addition to this, the launching of new medical therapies for treating joint pains and an increase in the allocation of funds for medical research by private players and government agencies will promote the expansion of the global market.
Deteriorating health observed in some of the patients inoculated with joint pain injections has posed a challenge to market growth
Side effects and allergies observed in the subjects due to joint pain injections have proved to be a major hurdle in the growth of the global joint pain injections market. Apart from this, cartilage and nerve damage witnessed in some of the patients receiving joint pain injections has affected the production and sale of these medical products. Furthermore, skin discoloration and infections occurring in patients due to the use of joint pain inoculations have proven to be the biggest hurdle in the global joint pain injections industry growth.
The global joint pain injections market is divided into product, joint type, distribution channel, and region.
On basis of product, the global joint pain injections market is divided into hyaluronic acid injections, corticosteroid injections, platelet-rich plasma injections, and others. Moreover, in 2021, hyaluronic acid injections dominated the global market in terms of revenue. The surge in the segment can be attributed to the growing awareness about the clinical benefits offered by the product along with an increase in the approval of hyaluronic acid injections by authorities such as the U.S. FDA for treating joint pains.
In terms of joint type, the global joint pain injections market is sectored into knee and ankle, hip, shoulder and elbow, and others. Furthermore, the knee and ankle segment is anticipated to account for the major revenue share of the global market in the coming years. The segmental growth over the forecast timeline can be credited to humungous demand for intra-articular injections for effectively treating knee and ankle pains.
Based on distribution channels, the global joint pain injections industry is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. In addition, the hospital pharmacies segment contributed majorly towards the overall share of the industry across the globe in 2021. The segmental expansion is attributed to the massive need of hospitalizing people suffering from orthopedic disorders. However, the retail pharmacies segment is anticipated to account sizably for the global market share over the forecast timeline. The growth of the segment from 2022 to 2030 can be due to the presence of a robust retail pharmacy network in both emerging economies and developed countries.
Report Attributes | Report Details |
---|---|
Report Name | Joint Pain Injections Market |
Market Size in 2024 | USD 5.82 Billion |
Market Forecast in 2034 | USD 15.35 Billion |
Growth Rate | CAGR of 10.18% |
Number of Pages | 172 |
Key Companies Covered | Anika Therapeutics Inc., Zimmer Biomet, Bioventus LLC, Ferring B.V., Sanofi-aventis LLC, Pfizer Inc., Eli Lilly and Company, Flexion Therapeutics Inc., Teva Pharmaceuticals, AbbVie Inc., Alkem Laboratories, and others. |
Segments Covered | By Injection Type, By Joint Type, By Distribution Channel, By End User, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Recent Developments:
North America to dominate the global market during the forecast timeline
The North American region is slated to account majorly for the global joint pain injections market share by 2030. The growth of the joint pain injections business in the region can be attributed to a prominent surge in the number of patients suffering from musculoskeletal disorders. Apart from this, supportive government compensation policies will account notably for the regional market proceeds.
However, the Asia-Pacific joint pain injections market is set to garner the highest gains over the forecast timeframe. The growth of the regional market can be attributed to the rise in cases of rheumatoid arthritis and osteoarthritis witnessed in the people. Growing awareness about the effectiveness of new joint pain therapies among the population of Asia-Pacific will benefit the market profitability of the region.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the joint pain injections market on a global and regional basis.
The global joint pain injections market is dominated by players like:
By Injection Type
By Joint Type
By Distribution Channel
By End User
By Region
FrequentlyAsked Questions
The global joint pain injections market is expected to grow due to rising arthritis prevalence, growing elderly population, and demand for fast, targeted pain relief solutions.
According to a study, the global joint pain injections market size was worth around USD 5.82 Billion in 2024 and is expected to reach USD 15.35 Billion by 2034.
The global joint pain injections market is expected to grow at a CAGR of 10.18% during the forecast period.
North America is expected to dominate the joint pain injections market over the forecast period.
Leading players in the global joint pain injections market include Anika Therapeutics Inc., Zimmer Biomet, Bioventus LLC, Ferring B.V., Sanofi-aventis LLC, Pfizer Inc., Eli Lilly and Company, Flexion Therapeutics Inc., Teva Pharmaceuticals, AbbVie Inc., Alkem Laboratories, among others.
The report explores crucial aspects of the joint pain injections market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed